News & Updates

Who Is Eligible for NHS Weight Loss Injections in 2026? Full NHS Criteria Explained

Published On : 25th February, 2026

Who Is Eligible for NHS Weight Loss Injections in 2026? Full NHS Criteria Explained

Demand for NHS weight loss injections has increased significantly following recent Government announcements expanding GP involvement in obesity care.

Many patients are now asking whether they qualify for treatment through their GP — and why access remains limited despite growing availability.

Understanding NHS eligibility criteria is essential before seeking treatment.

Slinic’s Prices

Our transparent pricing structure reflects the increasing strength of the medication as you progress through the treatment cycles. Each pen provides a four-week supply of weight loss injections, supported by our expert clinical team. The costs for 2026 are fixed as follows:

Mounjaro Pricing

  • 2.5mg:£139.99
  • 5mg:£185.99
  • 7.5mg:£235.99
  • 10mg:£259.99
  • 12.5mg:£279.99
  • 15mg:£294.99

Wegovy Pricing

For patients considering different options for medical weight loss, Wegovy remains a robust alternative with a different pricing trajectory. Understanding these figures is essential for long-term planning, especially if your clinical needs require a specific medication profile. Our Wegovy pricing for 2026 includes:

  • 0.25mg:£99.99
  • 0.5mg:£109.99
  • 1mg:£114.99
  • 1.7mg:£159.99
  • 2.4mg:£209.99

Switching between different weight loss treatment options is a clinical decision that must be managed with specialist care. If you’re moving from Wegovy to Mounjaro, or vice versa, our prescribing doctors will guide you through a safe transition period. This ensures your metabolic rate remains stable while minimizing the risk of gastrointestinal discomfort. We prioritize clear escalation pathways and provide bespoke advice to ensure your transition is as tranquil as possible.

Ready to begin your journey with a specialist-led team? 

Start your weight loss consultation online today

NHS Weight Loss Injections Available in England

The NHS currently provides access to clinically approved weight loss medications such as tirzepatide (Mounjaro®) through a phased national rollout.

Prescribing began within general practice in 2025 and continues to expand gradually under new GP funding incentives introduced for 2026/27.

However, treatment remains prioritised for patients at highest clinical risk.

Current NHS Eligibility Criteria

To qualify for NHS weight loss injections through GP services, patients generally must meet strict medical requirements.

Patients must:

✅ Be aged 18 or over

✅ Have a Body Mass Index (BMI) of:

  • 40 or higher, or
  • 37.5 or higher for certain ethnic groups

AND

✅ Have multiple obesity-related health conditions, including:

  • Type 2 diabetes
  • High blood pressure
  • Cardiovascular disease
  • Obstructive sleep apnoea
  • Abnormal cholesterol levels
  • Severe mobility limitations

Expected Eligibility Changes From 2026

Eligibility thresholds are expected to widen slightly under the next NHS contract period:

  • BMI ≥35 with four weight-related conditions
    OR
  • BMI ≥40 with three weight-related conditions

Despite expansion, NHS treatment will continue to prioritise patients with significant medical complications first.

Why Many Patients Do Not Qualify

A large proportion of individuals seeking treatment fall outside NHS criteria.

You may not currently be eligible if:

  • Your BMI is between 27–39
  • You are seeking preventative treatment
  • You do not yet have diagnosed medical conditions
  • Local NHS prescribing pathways are not operational

This can be frustrating for patients motivated to improve their health earlier.

Alternative Access Through Clinician-Led Prescribing Clinics

While NHS services expand gradually, regulated prescribing clinics provide medically supervised treatment following clinical assessment.

At Slinic, patients undergo a full medical eligibility review conducted by qualified prescribing clinicians before treatment begins.

Patients receive:

✔ Independent prescriber assessment

✔ Evidence-based treatment planning

✔ Ongoing monitoring

✔ Lifestyle and dietary support

For many individuals, earlier intervention allows proactive management rather than waiting for disease progression.

Start your 2 minute consultation with Slinic today>

Final Thoughts

NHS access to weight loss injections continues to expand, but eligibility remains carefully prioritised.

Understanding criteria helps patients explore appropriate treatment pathways and make informed decisions about their long-term health.

Slinic’s Resources

Author: Slinic Clinical Pharmacy Team
Medical Reviewer: Shadeia Younis, Pharmacist Lead
Reviewed: March 2026

Safety Notice: This information is for educational purposes and doesn’t replace professional medical advice. Weight loss injections are prescription-only medicines (POMs) and require a consultation with a registered healthcare professional. If you experience severe side effects like intense abdominal pain, breathing difficulties, or swelling, contact emergency services immediately. Always read the patient information leaflet before starting any weight loss treatment

News & Updates

News & Updates

Explore the latest updates, expert tips, and health news from Slinic. Our blog covers treatments, new medications, and helpful advice for managing your health online.

Mounjaro Face: A Clinical Guide to Understanding and Avoiding Facial Volume Loss

Mounjaro Face: A Clinical Guide to Understanding and Avoiding Facial Volume Loss

By Shadeia Younis 10th May, 2026

What if the aesthetic cost of your health transformation wasn’t a side effect of the medication, but a manageable biological response to rapid…

Mounjaro Long-Term Use: What Happens After 1 Year?

Mounjaro Long-Term Use: What Happens After 1 Year?

By Shadeia Younis 9th May, 2026

Reaching the twelve-month milestone on your medical weight loss journey shouldn’t feel like a finish line. In reality, it marks a critical transition…

Mounjaro and Periods: Does It Affect Your Menstrual Cycle?

Mounjaro and Periods: Does It Affect Your Menstrual Cycle?

By Shadeia Younis 8th May, 2026

While clinical pharmacovigilance data from 2022 to 2025 indicates that gynecological hemorrhagic events occur in just 0.60% of tirzepatide cases, the…

Mounjaro and Pregnancy: Is It Safe? Clinical Guidance and Specialist Advice (2026)

Mounjaro and Pregnancy: Is It Safe? Clinical Guidance and Specialist Advice (2026)

By Shadeia Younis 7th May, 2026

Could the very treatment that restored your metabolic health and improved your fertility now pose a risk to your developing pregnancy? It’s a complex…

Mounjaro and Wegovy Together: Clinical Safety and Switching Protocols

Mounjaro and Wegovy Together: Clinical Safety and Switching Protocols

By Shadeia Younis 6th May, 2026

Doubling your dose of GLP-1 medications isn’t a shortcut to faster results; it’s a clinical overdose that risks permanent metabolic damage. We…